Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Capmatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET known ✓ | P08581 | 20/20 | 1.00 |
| ▸ | CDKL5 | O76039 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Capmatinib SCHEMBL29429714 | 1.00 | MET (1.00) | METCDKL5KCNH2 | |
| Capmatinib SCHEMBL1426819 | 1.00 | MET (1.00) | METCDKL5KCNH2 | |
| Capmatinib SCHEMBL30166924 | 0.99 | MET (0.98) | METCDKL5KCNH2 | |
| Capmatinib SCHEMBL30166922 | 0.99 | MET (0.98) | METCDKL5KCNH2 | |
| Capmatinib SCHEMBL1427109 | 0.99 | MET (0.98) | METCDKL5KCNH2 | |
| Capmatinib SCHEMBL31061495 | 0.99 | MET (0.98) | METCDKL5KCNH2 | |
| Capmatinib SCHEMBL29362883 | 0.98 | MET (0.97) | METCDKL5KCNH2 | |
| Capmatinib SCHEMBL3843257 | 0.98 | MET (0.95) | METCDKL5KCNH2 | |
| SCHEMBL3830506 | 0.93 | MET (0.88) | METCDKL5KCNH2 | |
| SCHEMBL20406804 | 0.93 | MET (0.86) | METCDKL5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2767 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| US-20260137681-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS IN COMBINATION WITH HGF-RECEPTOR INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2026-05-21 | — | — | US | claimed |
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | NANOTECH PHARMA INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4741395-A1 | NOVEL COMPOUND SENSITIVE TO NITROGEN MONOXIDE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Omniamed Co. Ltd (KR) | 2026-05-13 | — | — | EP | claimed |
| CN-122005807-A | Application of HGF receptor inhibitor in preparation of medicine for treating/preventing myasthenia gravis | 重庆医科大学附属第一医院 | 2026-05-12 | — | — | CN | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| WO-2026087699-A1 | NEW TREATMENT OF NON-SMALL CELL LUNG CANCER | PIERRE FABRE MEDICAMENT (FR) | 2026-04-30 | — | — | WO | claimed |
| WO-2026090174-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | BRYET US, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-12605395-B2 | Materials and methods for immunosuppressive tumor microenvironment-targeted cancer therapy | UNIVERSITY OF CINCINNATI (US) | 2026-04-21 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| EP-3973963-A1 | QUINOLINE DERIVATIVES FOR TREATMENT OF HEAD AND NECK CANCER | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-03-30 | — | — | EP | claimed |
| EP-3973964-A1 | QUINOLINE DERIVATIVE USED FOR COMBINATION TREATMENT OF SMALL CELL LUNG CANCER | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-03-30 | — | — | EP | claimed |
| WO-2022061202-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-24 | — | — | WO | claimed |
| WO-2022055893-A1 | PHARMACEUTICAL COMBINATION AND TUMOR TREATMENT | IDEAYA BIOSCIENCES INC. (US) | 2022-03-17 | — | — | WO | claimed |
| EP-3967310-A1 | QUINOLINE DERIVATIVE USED FOR SOFT TISSUE SARCOMA COMBINATION THERAPY | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-03-16 | — | — | EP | claimed |
| WO-2022043895-A2 | TREATMENT OF NON-SMALL LUNG CANCER WITH EGFR MUTATIONS | JANSSEN BIOTECH, INC. (US) | 2022-03-03 | — | — | WO | claimed |
| US-20220064306-A1 | Treatment of Non-Small Cell Lung Cancer with EGFR Mutations | JANSSEN BIOTECH, INC. | 2022-03-03 | — | — | US | claimed |
| WO-2022038038-A2 | MEANS FOR THE THERAPY OF TUMOR DISEASES | EPO EXPERIMENTELLE PHARMAKOLOGIE & ONKOLOGIE BERLIN-BUCH GMBH (DE) | 2022-02-24 | — | — | WO | claimed |
| EP-3957631-A1 | QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING EWING'S SARCOMA | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-02-23 | — | — | EP | claimed |
| WO-2022020967-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-02-03 | — | — | WO | claimed |